Kinder Morgan Energy Partners

Kinder Morgan Energy Partners ( KMP) is a pipeline transportation and energy storage company in North America that owns and manages a portfolio of energy transportation and storage assets. This stock is trading up 1% at $83.98 in recent trading.

Today's Volume: 1.02 million
Average Volume: 1.08 million
Volume % Change: 62%

From a technical perspective, KMP is bouncing modestly higher here right above its 200-day moving average at $83.07 with decent upside volume. This stock has been downtrending badly for the last few weeks, with shares dropping from its high of $89.89 to today's low of $83.10. During that drop, shares of KMP have been consistently making lower highs and lower lows, which is bearish technical price action. That said, shares of KMP have now found support at its 200-day, and if that level holds the stock could rebound sharply to the upside.

Traders should now look for long-biased trades in KMP as long as it's trending above its 200-day at $83.07 with strong upside volume flows. I would consider any upside volume day that registers near or above its three-month average action of 1.08 million shares as bullish. If KMP can maintain that trend, then this stock could easily rebound towards $86 to its 50-day moving average at $88.07.

To see more stocks rising on unusual volume, check out the Stocks Rising on Unusual Volume portfolio on Stockpickr.

-- Written by Roberto Pedone in Madison, Wis.


Follow Stockpickr on Twitter and become a fan on Facebook.

At the time of publication, author had no positions in stocks mentioned.

Roberto Pedone, based out of Madison, Wis., is an independent trader who focuses on technical analysis for small- and large-cap stocks, options, futures, commodities and currencies. Roberto studied international business at the Milwaukee School of Engineering, and he spent a year overseas studying business in Lubeck, Germany. His work has appeared on financial outlets including and You can follow Pedone on Twitter at or @zerosum24.

If you liked this article you might like

What Adam Feuerstein Got Right and Wrong About Biotech Stocks in 2016

2016 Was a Terrible Year for Biotech but the Tweets Were on Point

Corbus Pharma Bear Thesis Is Alive and Well on Sclerosis Drug Data Skewed Positive

Celldex Therapeutics (CLDX) Stock Up on Q2 Results

Celldex Therapeutics (CLDX) Is Strong On High Volume Today